302 related articles for article (PubMed ID: 18253152)
1. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.
Forsyth P; Roldán G; George D; Wallace C; Palmer CA; Morris D; Cairncross G; Matthews MV; Markert J; Gillespie Y; Coffey M; Thompson B; Hamilton M
Mol Ther; 2008 Mar; 16(3):627-32. PubMed ID: 18253152
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults.
Kicielinski KP; Chiocca EA; Yu JS; Gill GM; Coffey M; Markert JM
Mol Ther; 2014 May; 22(5):1056-62. PubMed ID: 24553100
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.
Roulstone V; Khan K; Pandha HS; Rudman S; Coffey M; Gill GM; Melcher AA; Vile R; Harrington KJ; de Bono J; Spicer J
Clin Cancer Res; 2015 Mar; 21(6):1305-12. PubMed ID: 25424857
[TBL] [Abstract][Full Text] [Related]
4. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.
Fares J; Ahmed AU; Ulasov IV; Sonabend AM; Miska J; Lee-Chang C; Balyasnikova IV; Chandler JP; Portnow J; Tate MC; Kumthekar P; Lukas RV; Grimm SA; Adams AK; Hébert CD; Strong TV; Amidei C; Arrieta VA; Zannikou M; Horbinski C; Zhang H; Burdett KB; Curiel DT; Sachdev S; Aboody KS; Stupp R; Lesniak MS
Lancet Oncol; 2021 Aug; 22(8):1103-1114. PubMed ID: 34214495
[TBL] [Abstract][Full Text] [Related]
5. All reovirus subtypes show oncolytic potential in primary cells of human high-grade glioma.
Alloussi SH; Alkassar M; Urbschat S; Graf N; Gärtner B
Oncol Rep; 2011 Sep; 26(3):645-9. PubMed ID: 21637921
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours.
Hwang CC; Igase M; Sakurai M; Haraguchi T; Tani K; Itamoto K; Shimokawa T; Nakaichi M; Nemoto Y; Noguchi S; Coffey M; Okuda M; Mizuno T
Vet Comp Oncol; 2018 Jun; 16(2):229-238. PubMed ID: 29076241
[TBL] [Abstract][Full Text] [Related]
7. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
[TBL] [Abstract][Full Text] [Related]
8. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas.
Schwer AL; Damek DM; Kavanagh BD; Gaspar LE; Lillehei K; Stuhr K; Chen C
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):993-1001. PubMed ID: 17967517
[TBL] [Abstract][Full Text] [Related]
9. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
[TBL] [Abstract][Full Text] [Related]
10. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.
Geletneky K; Kiprianova I; Ayache A; Koch R; Herrero Y Calle M; Deleu L; Sommer C; Thomas N; Rommelaere J; Schlehofer JR
Neuro Oncol; 2010 Aug; 12(8):804-14. PubMed ID: 20299703
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.
Li JL; Liu HL; Zhang XR; Xu JP; Hu WK; Liang M; Chen SY; Hu F; Chu DT
Gene Ther; 2009 Mar; 16(3):376-82. PubMed ID: 19092859
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.
Kolb EA; Sampson V; Stabley D; Walter A; Sol-Church K; Cripe T; Hingorani P; Ahern CH; Weigel BJ; Zwiebel J; Blaney SM
Pediatr Blood Cancer; 2015 May; 62(5):751-8. PubMed ID: 25728527
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.
Friedman GK; Johnston JM; Bag AK; Bernstock JD; Li R; Aban I; Kachurak K; Nan L; Kang KD; Totsch S; Schlappi C; Martin AM; Pastakia D; McNall-Knapp R; Farouk Sait S; Khakoo Y; Karajannis MA; Woodling K; Palmer JD; Osorio DS; Leonard J; Abdelbaki MS; Madan-Swain A; Atkinson TP; Whitley RJ; Fiveash JB; Markert JM; Gillespie GY
N Engl J Med; 2021 Apr; 384(17):1613-1622. PubMed ID: 33838625
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.
Vidal L; Pandha HS; Yap TA; White CL; Twigger K; Vile RG; Melcher A; Coffey M; Harrington KJ; DeBono JS
Clin Cancer Res; 2008 Nov; 14(21):7127-37. PubMed ID: 18981012
[TBL] [Abstract][Full Text] [Related]
15. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.
Comins C; Spicer J; Protheroe A; Roulstone V; Twigger K; White CM; Vile R; Melcher A; Coffey MC; Mettinger KL; Nuovo G; Cohn DE; Phelps M; Harrington KJ; Pandha HS
Clin Cancer Res; 2010 Nov; 16(22):5564-72. PubMed ID: 20926400
[TBL] [Abstract][Full Text] [Related]
16. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
Bigner DD; Brown MT; Friedman AH; Coleman RE; Akabani G; Friedman HS; Thorstad WL; McLendon RE; Bigner SH; Zhao XG; Pegram CN; Wikstrand CJ; Herndon JE; Vick NA; Paleologos N; Cokgor I; Provenzale JM; Zalutsky MR
J Clin Oncol; 1998 Jun; 16(6):2202-12. PubMed ID: 9626222
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.
Qiao J; Wang H; Kottke T; White C; Twigger K; Diaz RM; Thompson J; Selby P; de Bono J; Melcher A; Pandha H; Coffey M; Vile R; Harrington K
Clin Cancer Res; 2008 Jan; 14(1):259-69. PubMed ID: 18172278
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Patel S; DiBiase S; Meisenberg B; Flannery T; Patel A; Dhople A; Cheston S; Amin P
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):739-42. PubMed ID: 21353747
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
20. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
